EQH slides as Corebridge merger hangover meets 2026 mortality-driven earnings worries
Equitable Holdings (EQH) shares fell about 3.83% to $36.20 as investors continued to discount the company’s late-March all-stock merger agreement with Corebridge Financial. The decline also reflects renewed focus on 2026 earnings sensitivity tied to higher baseline mortality assumptions and a $350–$400 million Corporate & Other loss outlook.
1) What’s happening in the stock
Equitable Holdings (EQH) traded lower Thursday, down 3.83% to $36.20, as the market continued to reprice the company following its recently announced, all-stock combination with Corebridge Financial. The move extends a period of elevated volatility in EQH since the transaction announcement late last month.
2) The main catalyst: merger digestion and deal-risk repricing
EQH’s latest weakness is being driven by ongoing “deal digestion” after Equitable and Corebridge announced a definitive agreement to combine in an all-stock merger valuing the combined company at about $22 billion (based on March 25, 2026 closing prices). Investors are weighing execution risk, the timeline to close, and the possibility that near-term uncertainty can cap upside even if the strategic logic is viewed positively. (stockwatch.com)
3) Why the downside pressure persists: 2026 profitability sensitivity remains in focus
Beyond the deal overhang, investors have also refocused on near-term earnings sensitivity in Equitable’s insurance operations. Management’s prior commentary around updated baseline mortality assumptions and guidance for Corporate & Other losses in the $350 million–$400 million range for 2026 has remained a key sticking point for sentiment, even after steps taken to reduce risk exposure. (quiverquant.com)
4) What to watch next
Near-term trading is likely to track incremental merger details (regulatory steps, expected closing window, integration planning) and any updates that shift the market’s view of 2026 earnings volatility. The next major fundamental catalyst is the upcoming earnings report, where investors will look for confirmation on trajectory, capital return priorities, and whether mortality experience is stabilizing versus the raised baseline assumptions. (benzinga.com)